Guggenheim Upgrades Editas Medicine to Buy, Announces $5 Price Target

Benzinga · 3d ago
Guggenheim analyst Debjit Chattopadhyay upgrades Editas Medicine (NASDAQ:EDIT) from Neutral to Buy and announces $5 price target.